AstraZeneca has reportedly held preliminary talks with Bristol Myers Squibb over a potential merger that could create one of the world’s largest pharmaceutical companies, with a combined market value of nearly $400 billion. According to a Reuters source, it remains unclear whether discussions are ongoing. AstraZeneca declined to comment, while Bristol Myers did not immediately respond.
A merger would face significant regulatory scrutiny, particularly from U.S. antitrust authorities, due to the companies’ overlapping cancer drug portfolios. Both firms generate a substantial share of their revenue from oncology treatments, making competition concerns a key hurdle if negotiations progress.
The proposed deal would mark the first major pharmaceutical merger since 2020. Bristol Myers has been pursuing smaller acquisitions to strengthen its pipeline as key drugs approach patent expiry, while AstraZeneca continues to post strong growth driven by demand for its cancer and rare disease medicines.
Pic courtesy: google/ images are subject to copyright
